AFFITOPE ® AT04: a treatment with a future

AFFiRiS' proprietary compound AFFITOPE® AT04 is a potential candidate for first-in-class active immunotherapy targeting PCSK9. The efficacy of this therapy was recently confirmed in a large phase 1 clinical trial (Zeitlinger et al. 2021). Hypercholesterolemia is a chronic disease associated with an increased risk of cardiovascular disease, the leading cause of death worldwide. The collaboration with Frontier Biotechnlogies now enables AT04 to be further developed as a cost-effective and patient-friendly treatment alternative in China. Noel Barrett, PhD, CEO of AFFiRiS AG commented: “This collaboration further validates our AFFITOME® technology platform. It fuels our ongoing efforts to license AT04 globally as we see a growing need for efficacious treatments in hypercholesterolemia. Many thanks to Marco Steiner, Johannes Feilmair, and the whole E+H team for their support over the past months." Marco Steiner and Johannes Feilmair have significant expertise in corporate transactions involving the healthcare industry, and they spearheaded the E+H team working on this agreement. Advisors to Affiris AG: E+H Eisenberger + Herzog Attorneys at Law Marco Steiner (Partner, Corporate/M&A), Johannes Feilmair (Attorney, Corporate/M&A), Dr. Jana Eichmeyer (Partner, Employment Law), Judith Feldner (Partner, Antitrust Law), Fabian Larcher (Associate, Corporate/M&A), Alexander Reiter (Associate, Antitrust Law) KPMG (Tax Advisors) Andreas Kronawetter Lukas Plakolm Sonn & Partner (Patent Counsel) Dr. Daniel Alge Advant Beiten (Local Chinese Counsel) Susanne Rademacher Jenna.Wang-Metzner

About E+H:

E+H is a commercial law firm operating internationally, with offices in Vienna, Graz, and Klagenfurt. The firm regularly receives awards and top spots in international rankings and directories, such as Chambers & Partners Global & Europe, Legal 500, JUVE, and Mergermarket. https://www.eh.at/en/

About AFFiRiS AG:

AFFiRiS is a clinical-stage biotechnology company located in Vienna, Austria, with a vision of using the immune system to identify and target human proteins central to the development and progression of neurodegenerative and cardiometabolic diseases, based on its proprietary patented AFFITOME® technology. The Company’s ultimate goal is to improve the lives of patients suffering from these diseases by providing specific immunotherapies. www.affiris.com

Contact:

Marco Steiner T: +43 1 606 3647 E: [email protected] E+H Eisenberger + Herzog Rechtsanwalts GmbH Vienna Twin Towers, Wienerbergstraße 11 1100 Wien